130 related articles for article (PubMed ID: 35535636)
1. Long-term survival of dogs with stage 4 oral malignant melanoma treated with anti-canine PD-1 therapeutic antibody: A follow-up case report.
Igase M; Inanaga S; Tani K; Nakaichi M; Sakai Y; Sakurai M; Kato M; Tsukui T; Mizuno T
Vet Comp Oncol; 2022 Dec; 20(4):901-905. PubMed ID: 35535636
[TBL] [Abstract][Full Text] [Related]
2. Proof-of-concept study of the caninized anti-canine programmed death 1 antibody in dogs with advanced non-oral malignant melanoma solid tumors.
Igase M; Inanaga S; Nishibori S; Itamoto K; Sunahara H; Nemoto Y; Tani K; Horikirizono H; Nakaichi M; Baba K; Kambayashi S; Okuda M; Sakai Y; Sakurai M; Kato M; Tsukui T; Mizuno T
J Vet Sci; 2024 Jan; 25(1):e15. PubMed ID: 38311328
[TBL] [Abstract][Full Text] [Related]
3. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.
Maekawa N; Konnai S; Takagi S; Kagawa Y; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Deguchi T; Nakajima C; Kato Y; Yamamoto K; Uemura H; Suzuki Y; Murata S; Ohashi K
Sci Rep; 2017 Aug; 7(1):8951. PubMed ID: 28827658
[TBL] [Abstract][Full Text] [Related]
4. A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs.
Igase M; Nemoto Y; Itamoto K; Tani K; Nakaichi M; Sakurai M; Sakai Y; Noguchi S; Kato M; Tsukui T; Mizuno T
Sci Rep; 2020 Oct; 10(1):18311. PubMed ID: 33110170
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma.
Maekawa N; Konnai S; Nishimura M; Kagawa Y; Takagi S; Hosoya K; Ohta H; Kim S; Okagawa T; Izumi Y; Deguchi T; Kato Y; Yamamoto S; Yamamoto K; Toda M; Nakajima C; Suzuki Y; Murata S; Ohashi K
NPJ Precis Oncol; 2021 Feb; 5(1):10. PubMed ID: 33580183
[TBL] [Abstract][Full Text] [Related]
6. Safety and clinical efficacy of an anti-PD-L1 antibody (c4G12) in dogs with advanced malignant tumours.
Maekawa N; Konnai S; Hosoya K; Kim S; Kinoshita R; Deguchi T; Owaki R; Tachibana Y; Yokokawa M; Takeuchi H; Kagawa Y; Takagi S; Ohta H; Kato Y; Yamamoto S; Yamamoto K; Suzuki Y; Okagawa T; Murata S; Ohashi K
PLoS One; 2023; 18(10):e0291727. PubMed ID: 37792729
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.
Maekawa N; Konnai S; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Takagi S; Kagawa Y; Nakajima C; Suzuki Y; Kato Y; Murata S; Ohashi K
PLoS One; 2016; 11(6):e0157176. PubMed ID: 27276060
[TBL] [Abstract][Full Text] [Related]
8. Electrochemotherapy in treatment of canine oral malignant melanoma and factors influencing treatment outcome.
Tellado MN; Maglietti FH; Michinski SD; Marshall GR; Signori E
Radiol Oncol; 2020 Mar; 54(1):68-78. PubMed ID: 32187017
[TBL] [Abstract][Full Text] [Related]
9. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma.
Ottnod JM; Smedley RC; Walshaw R; Hauptman JG; Kiupel M; Obradovich JE
Vet Comp Oncol; 2013 Sep; 11(3):219-29. PubMed ID: 23909996
[TBL] [Abstract][Full Text] [Related]
10. Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial.
Riccardo F; Tarone L; Camerino M; Giacobino D; Iussich S; Barutello G; Arigoni M; Conti L; Bolli E; Quaglino E; Merighi IF; Morello E; Dentini A; Ferrone S; Buracco P; Cavallo F
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580930
[TBL] [Abstract][Full Text] [Related]
11. Oral malignant melanomas and other head and neck neoplasms in Danish dogs--data from the Danish Veterinary Cancer Registry.
Brønden LB; Eriksen T; Kristensen AT
Acta Vet Scand; 2009 Dec; 51(1):54. PubMed ID: 20021647
[TBL] [Abstract][Full Text] [Related]
12. Programmed Cell Death Ligand 1 Expression in Canine Cancer.
Shosu K; Sakurai M; Inoue K; Nakagawa T; Sakai H; Morimoto M; Okuda M; Noguchi S; Mizuno T
In Vivo; 2016; 30(3):195-204. PubMed ID: 27107075
[TBL] [Abstract][Full Text] [Related]
13. Malignant melanoma in 63 dogs (2001-2011): the effect of carboplatin chemotherapy on survival.
Brockley LK; Cooper MA; Bennett PF
N Z Vet J; 2013 Jan; 61(1):25-31. PubMed ID: 22913610
[TBL] [Abstract][Full Text] [Related]
14. Effects of low-dose cyclophosphamide with piroxicam on tumour neovascularization in a canine oral malignant melanoma-xenografted mouse model.
Choisunirachon N; Jaroensong T; Yoshida K; Saeki K; Mochizuki M; Nishimura R; Sasaki N; Nakagawa T
Vet Comp Oncol; 2015 Dec; 13(4):424-32. PubMed ID: 23890026
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of bone invasion in canine oral malignant melanoma treated by surgery and anti-CSPG4 vaccination: A retrospective study on 68 cases (2010-2020).
Camerino M; Giacobino D; Manassero L; Iussich S; Riccardo F; Cavallo F; Tarone L; Olimpo M; Lardone E; Martano M; Del Magno S; Buracco P; Morello E
Vet Comp Oncol; 2022 Mar; 20(1):189-197. PubMed ID: 34392602
[TBL] [Abstract][Full Text] [Related]
16. Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy.
Maekawa N; Konnai S; Asano Y; Sajiki Y; Deguchi T; Okagawa T; Watari K; Takeuchi H; Takagi S; Hosoya K; Kim S; Ohta H; Kato Y; Suzuki Y; Murata S; Ohashi K
Sci Rep; 2022 Jun; 12(1):9265. PubMed ID: 35665759
[TBL] [Abstract][Full Text] [Related]
17. Reversing stage III oral adenocarcinoma in a dog treated with anti-canine PD-1 therapeutic antibody: a case report.
Xu S; Xie J; Wang S; Tang N; Feng J; Su Y; Li G
Front Vet Sci; 2023; 10():1144869. PubMed ID: 37252387
[TBL] [Abstract][Full Text] [Related]
18. A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis.
Tani H; Miyamoto R; Noguchi S; Kurita S; Nagashima T; Michishita M; Yayoshi N; Tamura K; Bonkobara M
BMC Vet Res; 2021 Apr; 17(1):147. PubMed ID: 33827546
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory Effects of a Reengineered Anthrax Toxin on Canine Oral Mucosal Melanomas.
Nishiya AT; Nagamine MK; Fonseca IIMD; Miraldo AC; Scattone NV; Guerra JL; Xavier JG; Santos M; Gomes COMS; Ward JM; Liu S; Leppla SH; Bugge TH; Dagli MLZ
Toxins (Basel); 2020 Mar; 12(3):. PubMed ID: 32121654
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.
Betof Warner A; Palmer JS; Shoushtari AN; Goldman DA; Panageas KS; Hayes SA; Bajwa R; Momtaz P; Callahan MK; Wolchok JD; Postow MA; Chapman PB
J Clin Oncol; 2020 May; 38(15):1655-1663. PubMed ID: 32053428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
